Israeli biotech firm successfully reverses human bone loss in early trial

The innovation could lead to the possibility of regrowing larger bones in the rest of the body.

By REUTERS
December 7, 2016 12:55
1 minute read.

Lab-grown bones successfully transplanted, says Israeli firm

Lab-grown bones successfully transplanted, says Israeli firm

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Israeli biotech company Bonus Biogroup's lab-grown, semi-liquid bone graft was successfully injected into the jaws of 11 people to repair bone loss in an early stage clinical trial, it said on Monday.

The material, grown in a lab from each patient's own fat cells, was injected into and filled the voids of the problematic bones. Over a few months it hardened and merged with the existing bone to complete the jaw, it said.

Be the first to know - Join our Facebook page.


The announcement was made in a statement to the Tel Aviv Stock Exchange and Bonus Biogroup is presenting its results at the International Conference on Oral and Maxillofacial Surgery in Spain on Monday.

The company, which has raised $14 million, said it plans to dual list on Nasdaq in the coming months.

"For the first time worldwide, reconstruction of deficient or damaged bone tissue is achievable by growing viable human bone graft in a laboratory, and transplanting it back to the patient in a minimally invasive surgery via injection," said Chief Executive Shai Meretzki.

Meretzki previously founded Pluristem Therapeutics , which works with stem cells and is one of the more advanced Israeli biomed companies.

Ora Burger, vice president of regulation affairs at Bonus Biogroup, told Reuters the transplant "was 100 percent successful in all 11 patients".

"Now we are going to conduct a clinical study in the extremities, long bones," she said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Economics
September 23, 2018
Trump economy

By DAVID ZWEBNER, SELWYN GERBER